Lead Pharma - Specialized in difficult to address drug targets
Lead Pharma Holding BV (LP) discovers and develops innovative small-molecule drugs for the treatment of autoimmune diseases and cancer. The company has built a versatile, comprehensive, proprietary drug design platform to develop novel, attractive compounds against drug targets which require superior R&D capabilities and expertise. Lead Pharma has an experienced executive board and a team with strong industry expertise in large pharmaceutical and/or biotech companies, including Organon, Schering-Plough, Merck, Janssen Pharmaceutica, Crucell, BioMérieux, and Numico. The company was founded in 2007 as a spinoff from the prestigious Hubrecht Institute and the University Medical Center in Utrecht, the Netherlands.